Significant association with SNP and survival outcome across cohorts
| SAMHD1 SNPs . | EFS . | OS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| rs7265241 A>G | AML02 (n = 167) | |||
| Unadjusted analysis† | 1.926 (1.046-3.547) | .035 | 2.410 (1.223-4.771) | .012 |
| Risk-group adjusted analysis† | 1.860 (1.010-3.428) | .046 | 2.235 (1.216-4.779) | .021 |
| AML08 (n = 233) | ||||
| Unadjusted analysis† | 1.264 (0.952-1.678) | .104 | 1.439 (1.043-1.986) | .027 |
| Risk-group adjusted analysis† | 1.823 (1.061-3.131) | .030 | 1.532 (1.042-1.987) | .010 |
| AAML1031 (n = 849) | ||||
| Unadjusted analysis‡ | 2.722 (1.538-4.816) | .001 | 2.214 (1.253-3.912) | .006 |
| Risk-group adjusted analysis‡ | 2.581 (1.458-4.567) | .001 | 1.202 (1.253-3.753) | .009 |
| rs1291141 T>G | AML02 (n = 167) | |||
| Unadjusted analysis∗ | 1.204 (0.817-1.775) | .348 | 1.221 (0.772-1.933) | .393 |
| Risk-group adjusted analysis∗ | 1.309 (0.881-1.947) | .183 | 1.396 (0.761-1.959) | .166 |
| AML08 (n = 233) | ||||
| Unadjusted analysis‡ | 1.247 (0.911-1.707) | .167 | 1.548 (1.122-2.138) | .008 |
| Risk-group adjusted analysis‡ | 1.160 (0.847-1.589) | .355 | 1.427 (1.122-2.139) | .031 |
| rs1291128 T>C | AML02 (n = 163) | |||
| Unadjusted analysis† | 0.932 (0.699-1.240) | .628 | 0.778 (0.564-1.073) | .126 |
| Risk-group adjusted analysis† | 0.859 (0.644-1.146) | .300 | 0.716 (0.563-1.075) | .043 |
| SAMHD1 SNPs . | EFS . | OS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| rs7265241 A>G | AML02 (n = 167) | |||
| Unadjusted analysis† | 1.926 (1.046-3.547) | .035 | 2.410 (1.223-4.771) | .012 |
| Risk-group adjusted analysis† | 1.860 (1.010-3.428) | .046 | 2.235 (1.216-4.779) | .021 |
| AML08 (n = 233) | ||||
| Unadjusted analysis† | 1.264 (0.952-1.678) | .104 | 1.439 (1.043-1.986) | .027 |
| Risk-group adjusted analysis† | 1.823 (1.061-3.131) | .030 | 1.532 (1.042-1.987) | .010 |
| AAML1031 (n = 849) | ||||
| Unadjusted analysis‡ | 2.722 (1.538-4.816) | .001 | 2.214 (1.253-3.912) | .006 |
| Risk-group adjusted analysis‡ | 2.581 (1.458-4.567) | .001 | 1.202 (1.253-3.753) | .009 |
| rs1291141 T>G | AML02 (n = 167) | |||
| Unadjusted analysis∗ | 1.204 (0.817-1.775) | .348 | 1.221 (0.772-1.933) | .393 |
| Risk-group adjusted analysis∗ | 1.309 (0.881-1.947) | .183 | 1.396 (0.761-1.959) | .166 |
| AML08 (n = 233) | ||||
| Unadjusted analysis‡ | 1.247 (0.911-1.707) | .167 | 1.548 (1.122-2.138) | .008 |
| Risk-group adjusted analysis‡ | 1.160 (0.847-1.589) | .355 | 1.427 (1.122-2.139) | .031 |
| rs1291128 T>C | AML02 (n = 163) | |||
| Unadjusted analysis† | 0.932 (0.699-1.240) | .628 | 0.778 (0.564-1.073) | .126 |
| Risk-group adjusted analysis† | 0.859 (0.644-1.146) | .300 | 0.716 (0.563-1.075) | .043 |